Powered by OpenAIRE graph
Found an issue? Give us feedback
image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/ Качественная клиниче...arrow_drop_down
image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/
Качественная клиническая практика
Article . 2018
Data sources: DOAJ
Claim

This Research product is the result of merged Research products in OpenAIRE.

You have already added 0 works in your ORCID record related to the merged Research product.

Специалист по фармакологической безопасности в фармацевтической компании

descriptionPublicationkeyboard_double_arrow_right Article 01 Jun 2018 Russian Publisher:Izdatelstvo OKIJournal:Качественная клиническая практика (issn: 2588-0519, Copyright policy )

Специалист по фармакологической безопасности в фармацевтической компании

Abstract

Специалист по фармакологической безопасности лекарственных средств (ЛС) — это менеджер, который обеспечивает полное соответ­ствие процесса сообщения информации регулятор­ным органам по безопасности ЛС, соответствующее международным и локальным (российским) требова­ниям.

Keywords

надлежащая практика фармаконадзора, управление рисками, специалист по фарм­конадзору, серьёзная нежелательная лекарственная реакция, фармаконадзор, RS1-441, клинические исследования, Pharmacy and materia medica, безопасность лекарств, уполномоченное лицо по фармаконадзору, Medical technology, нежелательное явление, affiliate safety representative, R855-855.5, pharmacoviligance manager, мониторинг безопасности лекарственных препаратов

  • BIP!
    Impact byBIP!
    selected citations
    These citations are derived from selected sources.
    This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
    		 0
    popularity
    This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.
    		 Average
    influence
    This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
    		 Average
    impulse
    This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.
    		 Average
Powered by OpenAIRE graph
Found an issue? Give us feedback
selected citations
These citations are derived from selected sources.
This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
BIP!Citations provided by BIP!
popularity
This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.
BIP!Popularity provided by BIP!
influence
This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
BIP!Influence provided by BIP!
impulse
This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.
BIP!Impulse provided by BIP!
0
Average
Average
Average
gold